Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1
| Autor: | Ruosha Li, Karl Kieburtz, Rohit Dhall, Natividad Stover, Barbara C. Tilley, Allison W. Willis, John C. Morgan, Xuehan Ren, Robert A. Hauser, Anthony P. Nicholas, John L. Goudreau, James T. Boyd, Adriana Pérez, John Y. Fang, Dan Weintraub, Richard M. Zweig, Chadwick W. Christine, Jordan J. Elm, Maureen A. Leehey, Ivan Bodis-Wollner, Chizoba C. Umeh, Michael J. Aminoff |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Monoamine Oxidase Inhibitors Time Factors Parkinson's disease Severity of Illness Index 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Modified Rankin Scale Internal medicine Outcome Assessment Health Care Severity of illness medicine Humans Aged Rasagiline business.industry Selegiline Confounding Parkinson Disease Middle Aged medicine.disease Clinical trial 030104 developmental biology chemistry Ambulatory Disease Progression Female Neurology (clinical) business 030217 neurology & neurosurgery Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Parkinson's Disease. 7:117-127 |
| ISSN: | 1877-718X 1877-7171 |
| Popis: | BACKGROUND Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients. OBJECTIVE To perform a secondary analysis of NET-PD LS1 to determine if longer duration of MAO-B inhibitor exposure was associated with less clinical decline. METHODS The primary outcome measure was the Global Outcome (GO), comprised of 5 measures: change from baseline in the Schwab and England (ADL) scale, the 39-item Parkinson's Disease Questionnaire (PDQ-39), the UPDRS Ambulatory Capacity Scale, the Symbol Digit Modalities Test, and the most recent Modified Rankin Scale. A linear mixed model was used to explore the association between the cumulative duration of MAO-B inhibitor exposure and the GO, adjusting for necessary factors and confounders. Associations between MAO-B inhibitor exposure and each of the five GO components were then studied individually. RESULTS 1616 participants comprised the analytic sample. Mean observation was 4.1 (SD = 1.4) years, and 784 (48.5%) participants received an MAO-B inhibitor. The regression coefficient of cumulative duration of MAO-B inhibitor exposure (in years) on the GO was - 0.0064 (SE = 0.002, p = 0.001). Significant associations between duration of MAO-B inhibitor exposure and less progression were observed for ADL (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|